Department of Surgical Oncology, Ankara City Hospital, Ankara, Turkey.
Department of General Surgery, Dr.Abdurrahman Yurtaslan Research and Training Hospital, Ankara, Turkey.
Libyan J Med. 2021 Dec;16(1):1973761. doi: 10.1080/19932820.2021.1973761.
Signet ring cell carcinoma (SRCC) is a poorly cohesive subtype of gastric cancer. It is more aggressive than other types of gastric cancer. There is no special method for its treatment, but gastrectomy and lymphadenectomy is the standard approach. The aim of this study is to investigate postoperative outcomes of D1 lymphadenectomy and D1(+)lymphadenectomy in gastric SRCC.A total of 358 cases whohad a gastrectomy performed forthe diagnosis of gastric cancer between 2013 and 2019 in Ankara University Medical Faculty, Surgical Oncology Department were retrospectively investigated. In all, 128 of the cases had SRCC in the final pathology. We separated the cases into two types,D1 lymphadenectomy and D1(+) lymphadenectomy. The 5-year survival, early mortality, hospital mortality and postoperative complication rates were evaluated.There were 59 patients in the D1 group and 64 patients in the D1(+) group.Metastatic lymph node amount and therefore N stage was found to be significantly higher in the D1(+) group (p=0.00 and p=0.03, respectively). Postoperative chyle fistula was found to be significantly higher in the D1(+) group (p=0.003). There was no statistically significant difference between the groups with regard tomean survival (p=0.065);the 5-year mean survival was 21% in the D1 group and 7% in the D1(+) group. Present findings suggest that extended lymphadenectomy does not provide a benefit in cases of SRCC.
印戒细胞癌(SRCC)是一种胃黏附性差的胃癌亚型。它比其他类型的胃癌更具侵袭性。目前尚无针对其的特殊治疗方法,但胃切除术和淋巴结清扫术是标准方法。本研究旨在探讨胃 SRCC 行 D1 淋巴结清扫术和 D1(+)淋巴结清扫术的术后结果。
回顾性分析 2013 年至 2019 年在安卡拉大学医学院外科肿瘤学系行胃切除术诊断为胃癌的 358 例患者。最终病理诊断为 SRCC 的患者共 128 例。我们将病例分为 D1 淋巴结清扫术和 D1(+)淋巴结清扫术两组。评估 5 年生存率、早期死亡率、医院死亡率和术后并发症发生率。D1 组 59 例,D1(+)组 64 例。D1(+)组转移淋巴结数量和 N 分期明显高于 D1 组(p=0.00 和 p=0.03)。D1(+)组术后乳糜瘘的发生率明显较高(p=0.003)。两组间平均生存时间无统计学差异(p=0.065);D1 组 5 年平均生存率为 21%,D1(+)组为 7%。目前的研究结果表明,对于 SRCC 患者,扩大淋巴结清扫术并不能带来获益。